The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

About AiRNA Pharmaceuticals

AiRNA's focus is to develop RNAi drugs for cancer, inflammation, and infectious diseases.

AiRNA Pharmaceuticals Headquarter Location

Norwood, Massachusetts, 02062,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AiRNA Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AiRNA Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

  • Where is AiRNA Pharmaceuticals's headquarters?

    AiRNA Pharmaceuticals's headquarters is located at Norwood.

  • Who are AiRNA Pharmaceuticals's competitors?

    Competitors of AiRNA Pharmaceuticals include Reata Pharmaceuticals, Bellicum Pharmaceuticals, VentiRx Pharmaceuticals, Theraclone Sciences, GlycoMimetics and 12 more.

You May Also Like

M
Mimetogen Pharmaceuticals

Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.

N
Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

I
ISA Pharmaceuticals

ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.

N
NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

P
Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.